Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices 45779 

Justice will receive comments relating to 

the Consent Decree. Comments should 

be addressed to the Assistant Attorney 

General, Environment and Natural 

Resources Division, and either e-mailed 

to pubcomment-ees.enrd@usdoj.gov or 

mailed to P.O. Box 7611, U.S. 

Department of Justice, Washington, DC 

20044–7611. In either case, the 

comments should refer to United States 

v. Morrison Enterprises, LLC, and 

Cooperative Producers, Inc., Civil 

Action No. 8:08–00332–JFB–TDT, D.J. 

Ref. No. 90–11–3–431/2. 

The decree may be examined at the 

Office of the United States Attorney, 

District of Nebraska, 1620 Dodge Street, 

Suite 1400, Omaha, Nebraska, 68102. 

During the comment period, the 

Consent Decree may be examined on the 

following Department of Justice website: 

http://www.usdoj.gov/enrd/ 

Consent_Decrees.html . A copy of the 

Consent Decree may also be obtained by 

mail from the Consent Decree Library, 

P.O. Box 7611, U.S. Department of 

Justice, Washington, DC 20044–7611, or 

by faxing or e-mailing a request to Tonia 

Fleetwood (tonia.fleetwood@usdoj.gov), 

fax no. (202) 514–0097, phone 

confirmation number (202) 514–1547. In 

requesting a copy from the Consent 

Decree Library, please enclose a check 

in the amount of $38.00 (25 cents per 

page reproduction cost) payable to the 

United States Treasury or, if by e-mail 

or fax, forward a check in that amount 

to the Consent Decree Library at the 

stated address. 

Robert E. Maher, Jr., 

Assistant Section Chief Environmental 

Enforcement Section, Environment and 

Natural Resources Division. 

[FR Doc. E8–18044 Filed 8–5–08; 8:45 am] 

BILLING CODE 4410–15–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to Title 21 Code of Federal 

Regulations 1301.34(a), this is notice 

that on May 27, 2008, Chattem 

Chemicals, Inc., 3801 St. Elmo Avenue, 

Building 18, Chattanooga, Tennessee 

37409, made application by renewal to 

the Drug Enforcement Administration 

(DEA) for registration as an importer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Methamphetamine (1105) ............. II 

Phenylacetone (8501) ................... II 

Drug Schedule 

Raw Opium (9600) ....................... II 

Concentrate of Poppy Straw 

(9670).

II 

The company plans to import the 

listed controlled substances to 

manufacture bulk controlled substances 

for sale to its customers. 

No comments, objections, or requests 

for any hearings will be accepted on any 

application for registration or reregistration to import crude opium, 

poppy straw, concentrate of poppy 

straw, and coca leaves. As explained in 

the Correction to Notice of Application 

pertaining to Rhodes Technologies, 72 

FR 3417 (January 25, 2007), comments 

and requests for hearing on applications 

to import narcotic raw material are not 

appropriate. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances listed in schedule I or II, 

which fall under the authority of section 

1002(a)(2)(B) of the Act (21 U.S.C. 

952(a)(2)(B)) may, in the circumstances 

set forth in 21 U.S.C. 958(i), file 

comments or objections to the issuance 

of the proposed registration and may, at 

the same time, file a written request for 

a hearing on such application pursuant 

to 21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than September 5, 2008. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975 

(40 FR 43745), all applicants for 

registration to import a basic class of 

any controlled substance listed in 

schedule I or II are, and will continue 

to be, required to demonstrate to the 

Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: July 29, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–17975 Filed 8–5–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on June 

11, 2008, Almac Clinical Services Inc. 

(ACSI), 2661 Audubon Road, Audubon, 

Pennsylvania 19403, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the basic classes of 

controlled substances listed in schedule 

II: 

Drug Schedule 

Oxycodone (9143) ........................ II 

Fentanyl (9801) ............................. II 

The company plans to import small 

quantities of the listed controlled 

substances in dosage form to conduct 

clinical trials. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances may file comments or 

objections to the issuance of the 

proposed registration and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than September 5, 2008. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

mstockstill on PROD1PC66 with NOTICES